Urology Times staff

2121 PARK ST


Dr. Laura Sena discusses bipolar androgen therapy for prostate cancer

December 02, 2022

“This is different from other standard-of-care therapies for prostate cancer because usually we are inhibiting androgen receptor (AR) activity and here we’re actually stimulating AR,” explained Laura Anne Sena, MD, PhD.

Dr. Galsky explains the biomarker challenge with adjuvant immunotherapy in urothelial cancer

December 02, 2022

“In the adjuvant setting, we have a ‘double biomarker problem.’ Not only don’t we know which drugs work best in which patients, we actually don’t even know which patients need additional systemic treatment because many patients are already cured with surgery,” says Matthew Galsky, MD.